PRODUCT LITERATURE

Phase I Trial of Docetaxel Administered by Weekly Infusion in Patients With Advanced Refractory Cancer

---

Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2
every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We
investigated a weekly schedule of docetaxel in an attempt to alter the toxicity profile and improve the therapeutic index

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Docetaxel

Specific Detail Info

J Clin Oncol 16:2164-2168

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment